Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Alglucosidase alfa
Drug ID BADD_D00071
Description Aglucosidase alfa consists of the human enzyme acid alpha-glucosidase (GAA) which is essential for the degradation of glygogen to glucose in lysosomes. It is encoded by the most predominant of nine observed haplotypes of this gene. Aglucosidase alfa is produced by recombinant DNA technology in a Chinese hamster ovary cell line. Alglucosidase alfa degrades glycogen by catalyzing the hydrolysis of a-1,4- and a-1,6- glycosidic linkages of lysosomal glycogen. Structurally, Alglucosidase alfa is a glycoprotein with a calculated mass of 98,008 daltons for the 883 residue mature polypeptide chain, and a total mass of approximately 109,000 daltons, including carbohydrates. It is used for the treatment of Pompe disease (GAA deficiency) in infants and pediatric patients.
Indications and Usage For the treatment of Pompe disease (GAA deficiency) in infants and pediatric patients.
Marketing Status approved
ATC Code A16AB07
DrugBank ID DB01272
KEGG ID D03207
MeSH ID C509951
PubChem ID Not Available
TTD Drug ID D07DUU
NDC Product Code 58468-0160
UNII DTI67O9503
Synonyms GAA protein, human | LYAG protein, human | acid alpha-glucosidase, human | acid maltase, human | glucosidase, alpha; acid (Pompe disease, glycogen storage disease type II), human | lysosomal alpha-glucosidase, human | alglucosidase alfa | rhGAA | recombinant human acid alpha-glucosidase | Nexviazyme | avlglucosidase alfa | Myozyme
Chemical Information
Molecular Formula Not Available
CAS Registry Number 420784-05-0
SMILES Not Available
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Agitation19.06.02.001; 17.02.05.012--
Anaphylactic reaction24.06.03.006; 10.01.07.001--
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Apnoea22.02.01.001--
Arthralgia15.01.02.001--
Back pain15.03.04.005--
Blood pressure increased13.14.03.005--Not Available
Cardiac arrest02.03.04.001--
Chest discomfort02.02.02.009; 22.12.02.002; 08.01.08.019--Not Available
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.011--Not Available
Chills15.05.03.016; 08.01.09.001--
Cold sweat08.01.03.024; 23.02.03.002--Not Available
Conjunctivitis11.01.06.012; 06.04.01.002--
Constipation07.02.02.001--
Cough22.02.03.001--
Cyanosis23.06.04.005; 24.03.01.007; 02.11.04.004; 22.02.02.007--
Diarrhoea07.02.01.001--
Discomfort08.01.08.003--Not Available
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Dyspepsia07.01.02.001--
Dyspnoea02.11.05.003; 22.02.01.004--
Ear pain04.03.01.003--
Epistaxis24.07.01.005; 22.04.03.001--
Erythema23.03.06.001--Not Available
Fatigue08.01.01.002--
Feeling hot08.01.09.009--Not Available
Flushing08.01.03.025; 24.03.01.002; 23.06.05.003--
Gastroenteritis11.01.07.004; 07.19.03.001--Not Available
Glomerulonephritis membranous20.05.01.007--Not Available
The 1th Page    1 2 3 4    Next   Last    Total 4 Pages